Prevalence of HIV and other infections and correlates of needle and syringe sharing among people who inject drugs in Podgorica, Montenegro: a respondent-driven sampling survey by Dragan Lausevic et al.
Lausevic et al. Harm Reduction Journal (2015) 12:11
DOI 10.1186/s12954-015-0039-0RESEARCH Open AccessPrevalence of HIV and other infections and
correlates of needle and syringe sharing among
people who inject drugs in Podgorica, Montenegro:
a respondent-driven sampling survey
Dragan Lausevic1, Senad Begic1, Boban Mugosa1, Natasa Terzic1, Zoran Vratnica1, Itana Labovic2 and Ivana Bozicevic3*Abstract
Background: People who inject drugs (PWID) have significantly higher rates of blood borne and sexually
transmitted infections due to unsafe injecting practices and risky sexual behaviors.
Methods: We carried out an HIV bio-behavioral survey using respondent-driven sampling (RDS) in people who use
drugs (PWID) in Podgorica, Montenegro in 2013 in order to determine the prevalence of HIV, hepatitis C (HCV),
hepatitis B surface antigen (HBsAg) and risk behaviors. Data were analyzed using RDS Analyst and SPSS 12.0
to obtain prevalence estimates of key bio-behavioral indicators and assess correlates of needle and syringe
sharing using multivariate logistic regression.
Results: A total of 402 PWID were recruited. HIV prevalence was 1.1%, while the prevalence of HCV and
HBsAg was 53.0% and 1.4%, respectively. In the multivariate analysis, significant correlates of needle and
syringe sharing in the past month were being older than 26 years, female, injecting drugs more than once
per day, injecting in parks or on streets, not being able to obtaining free-of-charge sterile needles and syringes
and reporting more than four partners in the past 12 months.
Conclusions: The results indicate that the HIV epidemic in PWID in Montenegro might still be at a low level, though
the HCV epidemic is well-established.
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People who inject drugs (PWID) have significantly higher
rates of blood borne and sexually transmitted infections
(STIs) due to unsafe injecting practices and risky sexual
behaviors [1]. Unsafe sexual behaviors facilitate transmis-
sion of STIs to their sexual partners, thus increasing the
risk of the spread of HIV and other STIs [2].
Montenegro, a former Yugoslav republic, is a small,
newly independent country in southeastern Europe with
a population of 620,000 people and a territory of around
13,000 km2. Podgorica, the capital of Montenegro, is the
largest city with around 200,000 inhabitants, constituting* Correspondence: Ivana.Bozicevic@lshtm.ac.uk
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unless otherwise stated.almost a third of a total population of Montenegro [3].
Podgorica is situated almost in the geographical center
of the country.
Since the beginning of HIV case reporting in 1989 until
the end of 2013, 153 HIV cases were reported of whom
five (2%) were reported as being due to injecting drug use,
42% as homosexual transmission and 44% as heterosexual
transmission [4]. In the period 2005–2013, the number
of newly reported cases of HIV ranged from 1.1 to 2.2 per
100,000 population.
HIV prevention interventions and harm reduction pro-
grams in PWID have been available in Montenegro since
2004 [5]. Currently, there are two drop-in centers for
PWID in Podgorica established in 2010 and one center for
Voluntary and Confidential HIV Counseling and Testing
(VCCT) established in 2003. The services of the Center forl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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2005 while those of the Center for Rehabilitation of Drug
Addicts since 2008. Drop-in centers are managed by two
non-governmental organizations (NGOs) while the VCCT
is operated by the Institute for Public Health (IPH). PWID
can obtain sterile injecting equipment free-of-charge at
drop-in centers and via outreach services, as well as at the
premises of the Primary Health Care Center in Podgorica.
The Global Fund to Fight AIDS, Tuberculosis and Malaria
has been a major funding source for HIV prevention
among key populations in Montenegro since 2006.
Integrated bio-behavioral surveys (IBBS) using respondent-
driven sampling (RDS) were implemented in Podgorica in
2008 and 2011 and found an HIV prevalence of 0.4% in
2008 and 0.3% in 2011, while the prevalence of hepatitis C
(HCV) was 53.6% and 55.0%, respectively [6,7].
The aim of this paper is to present the results of the
IBBS carried out in PWID in Podgorica in 2013, specifically
the prevalence of HIV, HCV, and hepatitis B virus surface
antigen (HBsAg), and behaviors relevant for transmission
of HIV and HCV, as well as correlates of sharing of needles
and syringes for drug injection.
Methods
Sampling
We conducted a cross-sectional bio-behavioral survey
among PWID in Podgorica using RDS [8,9]. Recruitment
was initiated with five seeds (initial participants), of whom
four were males and one female. Seeds were diverse in re-
spect to age and a place of residence in the city. Seeds, as
well as each participant who completed the survey, were
provided with three coupons to be used in recruiting max-
imum of three eligible participants. Eligible participants
were individuals older than 18 years living in Podgorica
for at least 3 months during 12 months before the survey
and who injected drugs for non-medical purposes in a
month preceding the survey. Before agreeing to partici-
pate in the survey, participants were described the nature
and characteristics of the survey and were asked for a ver-
bal consent to participate. Following the consent, partic-
ipants completed a questionnaire and were afterwards
provided with pre-test HIV counseling and taken a sam-
ple of venous blood. Primary monetary incentive and
three coupons for peer recruitment were given to partici-
pants after completion of the abovementioned steps of the
survey. Participants were instructed to re-visit the survey
site in 14 days in order to collect recruitment-related sec-
ondary incentives and test results. Post-test counseling
was provided after issuing HIV, HCV, and HBsAg test re-
sults. Data collection lasted from November to December
2013.
A sample size calculation was designed to detect a 9%
decline in needle and syringe sharing in the past month
with 80% power and an alpha error of 5%, from a valueof 13.6% in the survey carried out in 2011. It was esti-
mated that the sample size of 376 PWID was needed
and that was rounded up to 400 participants.
Behavioral questionnaire
We used the same behavioral questionnaire as in the 2011
survey, with minor modifications. The questionnaire was
based on a standardized behavioral questionnaire for PWID
published by the Family Health International and was
slightly modified and adapted to the country context [10].
It sought data on socio-demographic status, knowledge re-
garding the modes of HIV transmission, patterns of sexual
and drug using behaviors, past HIV testing, and awareness
and utilization of harm reduction services. A questionnaire
was self-administered. In case that a participant needed
help during completion of a questionnaire, trained study
staff provided appropriate explanations and assistance.
Data were also collected on participants’ social network
sizes that were assessed as the number of PWID they know
by name, are older than 18 years, who lived in Podgorica,
and have seen them in the past 3 months.
Laboratory methods
Blood samples were tested in the laboratory of the Center
for Medical Microbiology of the IPH, which serves as a
national referral center for HIV testing. Serum samples
were tested for the presence of HIV-1/2 antibodies and
p24 antigen using ELISA (HIV Ab&Ag, Dia.Pro Diagnostic
Bioprobes srl., Milano, Italy), while confirmatory HIV-1/2
testing was done by NEW LAV BLOT I and NEW LAV
BLOT II (Bio-Rad, Marnes-la-Coquette, France). ELISA
was also used for detection of antibodies against HCV
(HCV Ab, Dia.Pro Diagnostic Bioprobes srl., Milano, Italy)
and HBsAg (HBsAgone Version ULTRA, Dia.Pro Diagnostic
Bioprobes srl., Milano, Italy).
All survey procedures were conducted by trained
personnel. Ethical approval was granted by the Ethical
Committee of the IPH in Podgorica.
Analysis
Univariate analysis to calculate key socio-demographic,
behavioral, and biological indicators was done using
Respondent-Driven Sampling Analyst (RDS-A) statistical
software that provides weighted population estimates
with 95% confidence intervals (95% CI) of the variables of
interests [11]. Bivariate and multivariate logistic regres-
sion analysis was done using SPSS 12 statistical soft-
ware package on unweighted data (SPSS for Windows,
Version 12.0). Data on seeds were excluded from the ana-
lysis, as per RDS analysis procedures.
We assessed factors associated with needle and syringe
sharing in a month before participation in the survey
using logistic regression analyses. Sharing needles and sy-
ringes was defined by either giving needles and syringes
Lausevic et al. Harm Reduction Journal (2015) 12:11 Page 3 of 7that a respondent used by himself/herself to other PWID
or using needles and syringes for injecting drugs that were
already used by other PWID. The following variables were
considered potential correlates of needle and syringe shar-
ing: age, gender, monthly income, frequency of injections in
the past month, number of partners in the last 12 months,
injecting drugs in an outdoors setting (in parks or on
streets) during past month, and being given free-of-charge
needles and syringes by NGOs and the Primary Health
Care Centre in the past 12 months. Results are presented
as odds ratios (ORs) with 95% CI. Age and gender as con-
founders and variables associated with sharing needles
and syringes at the level of p < 0.05 in the bivariate analysis
were included in the multivariate logistic regression
model. The cutoff for considering a result to be statisti-
cally significant in the multivariate analysis was set up at
p < 0.05.
Missing values were excluded from the analyses.
Results
Recruitment patterns, socio-demographic characteristics,
and knowledge of HIV
Five seeds recruited a total of 402 eligible participants.
The median social network size was six (interquartile
range (IQR) = 3–10). The mean number of waves was
8.2, ranging from 4 to 10. We distributed a total of 1,202
coupons.
A majority of survey participants were men (90.1%).
The median age of respondents was 32 (IQR 28–35) years.
A majority of PWID completed either secondary (60.5%)
or primary (23.5%) school. Being unemployed was re-
ported by 58.2% of respondents, while 64.7% reported an
income of <150 EUR per month.
A majority of respondents knew that it is possible to
decrease the risk of HIV transmission by not sharing
needles and other injecting equipment (86.1%) and by
proper and consistent use of condoms during sexual
intercourse (85.4%), but only 37.1% had comprehensive
knowledge of HIVa.
HIV testing and HIV, HCV, and HBsAg prevalence
A majority of PWID (75.6%) knew where it was possible
to be tested for HIV.
Never been tested for HIV was reported by 57.7% of
PWID while 18.9% were tested during the last 12 months.
HIV prevalence was 1.1%, while the prevalence of HCV
and HBsAg was 53.0% and 1.4%, respectively. HCV preva-
lence was 31.5% in those younger than 25 years of age and
57.4% among older than 26 years.
Sexual risk behaviors
A majority of PWID (70.1%) were sexually active during
a month preceding the survey. A half of respondents re-
ported having regular partners at the time of the survey,and 24.2% used condom at last intercourse with a regu-
lar partner (Table 1). Before having the first sexual inter-
course with a current or last regular partner, only 28.6%
of PWID discussed HIV status with that partner. Having
non-regular partners during the past 12 months was re-
ported by 62.2% of PWID, and 46.4% of these reported
consistent condom use with this type of partners.
A substantial number (68.9%) reported more than one
sexual partner in the past 12 months while more than a
third of PWID had four or more sexual partners in that
time period.
Almost a half of PWID had experience of commercial
sex, either in terms of paying or being paid for sex or ex-
changing sex for drugs, and 79.5% of these reported using
a condom during the last commercial sexual intercourse.
A majority of participants (84.6%) reported using drugs
sometimes or often before sexual intercourse in the past
12 months.
Drug use behaviors
The median age of the first injecting drug use was 24 years
(IQR = 20–28), while the median duration of injecting
drugs was 5 years (IQR = 2–9). The vast majority of PWID
reported using heroin (95.7%) followed by cocaine (4.3%),
and no one reported using more than one type of a drug
in a month preceding the survey (Table 1).
Injecting drugs at least once per day in a month before
a survey was reported by 45.4% of PWID. Approximately
two out of five respondents reported never sharing nee-
dles and syringes while injecting drugs. Sharing injecting
equipment at least once during a month preceding the
survey was reported by 14.1% of PWID while 8.4% shared
injecting equipment last time they injected.
All but one respondent reported that they could obtain
sterile injecting equipment when they needed it, either
free-of-charge from harm reduction services or by buy-
ing them at pharmacies.
As sources of free-of-charge needles and syringes in
the past 12 months respondents mentioned mobile out-
reach teams (8.0%), primary health-care centers (17.9%),
and drop-in centers (53.5%).
A substantial proportion of respondents (60.8%) re-
ported that they bought needles and syringes at pharma-
cies in the past 12 months.
During the past 12 months, 75.8% of PWID received
risk-reduction counseling or some form of education about
HIV prevention.
Table 2 shows the prevalence of needle and syringe
sharing in the past month by socio-demographic and be-
havioral variables and results of bivariate and multivari-
ate logistic regression.
After adjustment in the multivariate analysis, signifi-
cantly higher odds of needle and syringe sharing were found
among PWID who were older than 26 years (aOR = 4.2,
Table 1 Sexual and injecting drug use behaviors in people who inject drugs in Podgorica, Montenegro, 2013
n/N Sample prevalence %a RDSb prevalence
estimates % (95% CI)c
Currently has regular sexual partner 217/401 54.1 50.9 (44.1–57.6)
Used condom during last sex with regular partnerd 100/396 25.3 24.2 (19.1–29.2)
Discussed HIV status before having first sexual intercourse with regular partnerd 127/401 31.7 28.6 (22.8–34.3)
Had non-regular sexual partner in the past 12 months 251/399 62.9 62.2 (56.2–68.4)
Used condoms consistently during sexual intercourse with non-regular partners
in the past 12 months
109/251 43.4 46.4 (37.1–55.8)
Total number of sex partners in the past 12 months
0–1 123/392 31.4 31.1 (25.3–36.8)
2–3 121/392 30.9 34.0 (27.2–40.8)
4–5 63/392 16.1 16.7 (11.8–21.5)
6–10 63/392 16.1 13.7 (9.6–17.8)
≥11 22/392 5.6 4.5 (2.3–6.8)
Ever had sexual intercourse for which received or gave money or drugs 216/400 54.0 48.8 (42.0–55.6)
Used condom during last sexual intercourse for which gave or received money or drugs 169/216 78.2 79.5 (71.6–87.5)
Used drugs before sexual intercourse in the past 12 months
Never 16/398 4.0 3.5 (1.4–5.5)
Rarely 30/398 7.5 11.9 (7.4–16.4)
Sometimes 83/398 20.9 22.4 (17.0–27.8)
Often 269/398 62.2 62.2 (55.9–68.4)
Type of drugs used in the past month
Heroin 381/401 95.0 95.7 (93.2–98.3)
Cocaine 20/401 5.0 4.3 (1.7–6.8)
Frequency of injecting drugs in the past month
Once per month 9/402 2.2 3.0 (0.6–5.4)
Few times per month 68/402 16.9 23.1 (15.7–30.4)
Once per week 9/402 2.2 1.5 (0.4–2.6)
Several times per week 91/402 22.6 27.0 (20.7–33.4)
Once per day 27/402 6.7 5.1 (2.8–7.3)
Several times per day 198/402 49.3 40.3 (33.3–47.3)
Ever shared needles or syringes with someone else during drug injection 260/402 64.7 60.4 (53.9–66.8)
Shared needles or syringes with someone else in the past month 57/399 14.3 14.1 (9.7–18.4)
Shared needles or syringes with someone else in the last episode of injection 31/401 7.7 8.4 (4.9–12.0)
Received drug dependence treatmente
Currently 25/399 6.3 6.1 (3.3–8.9)
Not currently, but in the past 160/399 39.8 37.1 (31.3–42.9)
Never 214/399 53.4 56.7 (50.6–62.8)
aUnweighted estimates.
bWeighted estimates; RDS = respondent-driven sampling.
c95% CI = 95% confidence interval.
dRefers to current or most recent regular partner.
eDrug dependence treatment included opioid substitution therapy (as maintenance treatment), inpatient detoxification, outpatient drug dependence treatment,
peer-based support groups.
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(aOR = 2.5, 95% CI 1.0-6.1), those who injected drugs
more frequently than once per day (aOR = 2.4, 95% CI1.3–4.7), those who reported injecting drugs in parks or
on streets in the past month (aOR = 2.6, 95% CI 1.3–5.4),
those who reported not being provided with free-of-
Table 2 Socio-demographic and behavioral correlates of sharing needles and syringes in the past month before a
survey in Podgorica, Montenegro, 2013 (unweighted analysis)
Variable n/N Prevalence of sharing needles
and syringes in the past month
before a survey (%) with 95% CI
Unadjusted OR Adjusted OR
(95% CI)a (95% CI)
Age group (years) p = 0.054 p = 0.010b
≤25 4/64 6.2 (2.4–15.0) 1.00 1.00
≥26 53/335 15.8 (12.3–20.1) 2.81 (0.98–8.08) 4.16 (1.44–14.77)
Sex p = 0.123 p = 0.039
Male 48/359 13.4 (10.2–17.3) 1.00 1.00
Female 9/40 22.5 (12.3–37.5) 1.88 (0.84–4.20) 2.53 (1.04–6.12)
Monthly income p = 0.041 p = 0.051
>300 EUR 4/68 5.9 (2.3–14.2) 1.00 1.00
≤301 EUR 52/329 15.8 (12.3–20.1) 3.00 (1.05–8.60) 4.13 (0.99–18.77)
Frequency of injecting in the past month p = 0.006 p = 0.008
Once per day or less 19/202 9.4 (6.1–14.2) 1.00 1.00
More than once per day 38/197 19.3 (14.4–25.4) 2.30 (1.27–4.15) 2.44 (1.25–4.73)
Number of sex partners in the past 12 months p = 0.023 p = 0.009
≤3 26/242 10.7 (7.4–15.3) 1.00 1.00
≥4 28/147 19.1 (13.5–26.1) 1.95 (1.09–3.48) 2.35 (1.24–4.46)
Injected drugs in parks or on streets in the past month p = 0.014 p = 0.010
No 41/330 12.4 (9.3–16.4) 1.00 1.00
Yes 16/66 24.2 (15.5–35.8) 2.25 (1.17–4.32) 2.61 (1.25–5.44)
Provided with free sterile needles and syringes in the
past 12 monthsc
p = 0.009 p = 0.008
Yes 49/381 12.9 (9.9–16.6) 1.00 1.00
No 6/16 37.5 (18.5–61.4) 4.06 (1.41–11.68) 5.74 (1.58–20.9)
aOR = odds ratio; 95% CI = 95% confidence interval.
bp values represent significance test for heterogeneity across the variable.
cThis refers to being given free-of-charge needles and syringes by NGOs and/or the Primary Health Care Centre.
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and those who had four and more sexual partners in the
last 12 months (aOR = 2.4, 95% CI 1.2–4.5).
Discussion
The HIV prevalence of 1.1% found in Podgorica in 2013
is higher than in the surveys done in 2008 and 2011,
though this finding still implies a low-level HIV epi-
demic in PWID. The prevalence of HCV was at a similar
level in 2013 (53.0%) as in 2008 and 2011.
Comparable HIV prevalence estimates were found in
most recent surveys conducted in PWID in other coun-
tries of ex-Yugoslavia: 3% in Belgrade, Serbia in 2005;
0%–0.5% in several cities in Bosnia and Herzegovina in
2011; 0 in Croatia in 2007 and in FYR Macedonia in
2010 [12-15]. However, epidemics of HCV in PWID are
well established in these countries—the prevalence in the
abovementioned surveys was 66% in Belgrade, Serbia,
23%–49% in several cities in Bosnia and Herzegovina,
44%–65% in several cities in Croatia, and 70% in Skopje,
FYR Macedonia [12-15].It is encouraging that almost all respondents in this sur-
vey as in the 2008 and 2011 surveys (96.8% and 99.6%, re-
spectively) reported that they could obtain sterile needles
and syringes for injecting.
Sharing needles and syringes in a month prior to the
survey was reported in 2013 by 14.1% of PWID, which is
very similar to the findings from the survey carried out in
2011 (13.6%) and substantially less than in 2008 (24.2%),
which might explain a stable prevalence of HCV in this
time period.
However, there are several findings that show current
gaps in HIV and HCV prevention and that have import-
ance for further development of interventions for pre-
vention of these infections in PWID in Montenegro.
Although a majority of PWID know where they can be
tested for HIV, the HIV testing uptake is low—less than
one in five respondents reported being tested for HIV in a
year before the survey. A high proportion of respondents
reported never being on drug dependence treatment. In-
terventions among PWID need to focus on ensuring bet-
ter access to drug dependence treatment as it is highly
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dependent injectors at risk for HIV and blood-borne infec-
tions [16,17].
Results of multivariate analysis highlighted that certain
groups may benefit from stronger harm reduction pro-
grams that emphasize importance of consistent use of
sterile injecting equipment, such as females who inject
drugs (FWID), those who report higher number of sex-
ual partners, and those who inject in outdoor settings.
It is well known that FWID are more difficult to reach
with HIV prevention services compared to males and
tend to engage in higher-risk injecting practices [18-21].
FWID usually depend on male partners for drugs and
injections, leading to elevated drug and equipment shar-
ing, and many engage in commercial sex. Given that
FWID may be at higher risk of HIV, particularly via sex-
ual transmission, there is a need to further explore bar-
riers that they face in accessing harm reduction services.
Separate prevalence assessment surveys can be done in
FWID only to determine the level of HIV, HCV, and
STIs in this sub-population and factors that expose them
to higher risk of acquiring these infections.
There is evidence that PWID who engage in high-risk
sexual behaviors might be more likely to engage in risky
injection practices [22-25]. In our survey, almost a half
of respondents reported ever selling or buying sex or ex-
changing it for drugs, and somewhat more than a half re-
ported non-regular partners in the past 12 months and
rather low condom use with such partners. Only a minor-
ity of respondents reported discussing HIV status before
having the first intercourse with regular partners.
Of note is that in our study, older PWID reported sig-
nificantly higher odds of needle and syringe sharing than
younger PWID, which is a finding that has relevance for
further intervention planning. Factors that put older
PWID at risk of harmful injecting practices should be
explored in Montenegro since research on the influence
of age on the patterns of drug use mainly demonstrated
that younger PWID are more likely than older PWID to
share injecting equipment and engage in high-risk inject-
ing behaviors [26-28].
Based on the results of this analysis, we recommend
that free and confidential HIV testing and counseling
should be more readily available for PWID as well as
drug dependence treatment and sexual heath interven-
tions that include screening for STIs, condom distribu-
tion programs, and promotion of safer sex practices.
Since those who inject in outdoor settings had higher
odds of needle and syringe sharing and a low propor-
tion of PWID reported obtaining free-of-charge injecting
equipment from outreach services, it is important to map
sites in Podgorica where PWID gather so that harm re-
duction programs can be more effectively strengthened
through outreach and mobile services.This study was not without limitation. Self-reported
behaviors are subject to social desirability and recall bias.
Refusals to participate are challenging to measure in
RDS and could have also biased the findings. RDS may
have resulted in under-recruitment of certain types of
participants, e.g., PWID with smaller injecting networks
and women [29]. Better recruitment of females who in-
ject drugs could have been achieved by having more fe-
male seeds. In the future HIV bio-behavioral surveys,
efforts should be made to achieve more effective recruit-
ment of FWID.
Conclusion
The current evidence shows that the HIV epidemic in
PWID in Montenegro is still at the low level, though the
HIV prevalence might have increased in the period
2011–2013. The HCV epidemic is well established in this
population as slightly more than a half of recruited PWID
were found to be HCV infected. It is of paramount im-
portance that targeted and effective interventions based
on the combination of behavioral, biomedical, and struc-
tural approaches are kept sustainable and continue to be
scaled up.
Endnote
aComprehensive knowledge of HIV meant knowing that
proper and consistent use of condoms during sexual inter-
course and having just one partner who is HIV negative
and has no other partners can reduce the risk of getting
HIV, knowing that a healthy-looking person can have HIV,
knowing that it is possible to decrease the risk of HIV
transmission by not sharing needles and other injecting
equipment and rejecting the two most common local mis-
conceptions about HIV transmission and prevention.Competing interests
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